Cargando…
Analytical validation, sample stability, and clinical evaluation of a new high-sensitivity cardiac troponin I immunoassay for use in dogs, with comparison to a previous ultrasensitive assay
Cardiac troponin I (cTnI) is considered the gold standard biomarker for myocardial injury and shows a high degree of homology between humans and dogs. The ADVIA Centaur XP High-Sensitivity Troponin I (AC-cTnI-HS) assay has been validated for use in humans but not dogs. The study objectives were to a...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10353792/ https://www.ncbi.nlm.nih.gov/pubmed/37463140 http://dx.doi.org/10.1371/journal.pone.0288801 |
_version_ | 1785074779793915904 |
---|---|
author | Wesselowski, Sonya Lidbury, Jonathan Saunders, Ashley B. Gordon, Sonya G. Suchodolski, Jan S. Steiner, Joerg M. |
author_facet | Wesselowski, Sonya Lidbury, Jonathan Saunders, Ashley B. Gordon, Sonya G. Suchodolski, Jan S. Steiner, Joerg M. |
author_sort | Wesselowski, Sonya |
collection | PubMed |
description | Cardiac troponin I (cTnI) is considered the gold standard biomarker for myocardial injury and shows a high degree of homology between humans and dogs. The ADVIA Centaur XP High-Sensitivity Troponin I (AC-cTnI-HS) assay has been validated for use in humans but not dogs. The study objectives were to analytically validate the AC-cTnI-HS assay in dogs, to assess correlation between the AC-cTnI-HS and a previous ADVIA Centaur TnI-Ultra (AC-cTnI-U) assay, to assess cTnI sample storage stability, and to clinically evaluate the AC-cTnI-HS assay in healthy dogs and dogs with cardiac disease. Canine serum samples were used for analytical validation. Intra- and inter-assay variability, dilutional parallelism, and spiking recovery were assessed. Samples from 196 client-owned dogs were evaluated (healthy dogs (n = 39) or dogs with congenital heart disease (n = 54), myxomatous mitral valve disease (n = 68), dilated cardiomyopathy (n = 15), or myocarditis (n = 20)). Inter- and intra-assay coefficient of variation (%CV) was between 2.8–41.4% and 3.8–30.2%, respectively, with pools with concentrations >20 pg/mL all having %CVs <10%. The observed to expected ratios for dilutional parallelism and spiking recovery experiments ranged between 92.3 and 266.7.0% and 84.3 and 108%, respectively. A strong correlation between the AC-cTnI-HS and AC-cTnI-U assays was observed (Spearman’s ρ = 0.927), though a proportional bias existed, with AC-cTnI-HS assay concentrations being proportionally lower than AC-cTnI-U assay concentrations. Serum samples stored at -80°C had stable cTnI measurements for up to 2.7 years and after a single freeze-thaw cycle. Healthy dogs and dogs with congenital heart disease had significantly lower cTnI concentrations than dogs in the other three groups. The AC-cTnI-HS assay precisely, reproducibly, and accurately measures cTnI concentrations in dog serum with cTnI concentrations >20 pg/mL. |
format | Online Article Text |
id | pubmed-10353792 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-103537922023-07-19 Analytical validation, sample stability, and clinical evaluation of a new high-sensitivity cardiac troponin I immunoassay for use in dogs, with comparison to a previous ultrasensitive assay Wesselowski, Sonya Lidbury, Jonathan Saunders, Ashley B. Gordon, Sonya G. Suchodolski, Jan S. Steiner, Joerg M. PLoS One Research Article Cardiac troponin I (cTnI) is considered the gold standard biomarker for myocardial injury and shows a high degree of homology between humans and dogs. The ADVIA Centaur XP High-Sensitivity Troponin I (AC-cTnI-HS) assay has been validated for use in humans but not dogs. The study objectives were to analytically validate the AC-cTnI-HS assay in dogs, to assess correlation between the AC-cTnI-HS and a previous ADVIA Centaur TnI-Ultra (AC-cTnI-U) assay, to assess cTnI sample storage stability, and to clinically evaluate the AC-cTnI-HS assay in healthy dogs and dogs with cardiac disease. Canine serum samples were used for analytical validation. Intra- and inter-assay variability, dilutional parallelism, and spiking recovery were assessed. Samples from 196 client-owned dogs were evaluated (healthy dogs (n = 39) or dogs with congenital heart disease (n = 54), myxomatous mitral valve disease (n = 68), dilated cardiomyopathy (n = 15), or myocarditis (n = 20)). Inter- and intra-assay coefficient of variation (%CV) was between 2.8–41.4% and 3.8–30.2%, respectively, with pools with concentrations >20 pg/mL all having %CVs <10%. The observed to expected ratios for dilutional parallelism and spiking recovery experiments ranged between 92.3 and 266.7.0% and 84.3 and 108%, respectively. A strong correlation between the AC-cTnI-HS and AC-cTnI-U assays was observed (Spearman’s ρ = 0.927), though a proportional bias existed, with AC-cTnI-HS assay concentrations being proportionally lower than AC-cTnI-U assay concentrations. Serum samples stored at -80°C had stable cTnI measurements for up to 2.7 years and after a single freeze-thaw cycle. Healthy dogs and dogs with congenital heart disease had significantly lower cTnI concentrations than dogs in the other three groups. The AC-cTnI-HS assay precisely, reproducibly, and accurately measures cTnI concentrations in dog serum with cTnI concentrations >20 pg/mL. Public Library of Science 2023-07-18 /pmc/articles/PMC10353792/ /pubmed/37463140 http://dx.doi.org/10.1371/journal.pone.0288801 Text en © 2023 Wesselowski et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Wesselowski, Sonya Lidbury, Jonathan Saunders, Ashley B. Gordon, Sonya G. Suchodolski, Jan S. Steiner, Joerg M. Analytical validation, sample stability, and clinical evaluation of a new high-sensitivity cardiac troponin I immunoassay for use in dogs, with comparison to a previous ultrasensitive assay |
title | Analytical validation, sample stability, and clinical evaluation of a new high-sensitivity cardiac troponin I immunoassay for use in dogs, with comparison to a previous ultrasensitive assay |
title_full | Analytical validation, sample stability, and clinical evaluation of a new high-sensitivity cardiac troponin I immunoassay for use in dogs, with comparison to a previous ultrasensitive assay |
title_fullStr | Analytical validation, sample stability, and clinical evaluation of a new high-sensitivity cardiac troponin I immunoassay for use in dogs, with comparison to a previous ultrasensitive assay |
title_full_unstemmed | Analytical validation, sample stability, and clinical evaluation of a new high-sensitivity cardiac troponin I immunoassay for use in dogs, with comparison to a previous ultrasensitive assay |
title_short | Analytical validation, sample stability, and clinical evaluation of a new high-sensitivity cardiac troponin I immunoassay for use in dogs, with comparison to a previous ultrasensitive assay |
title_sort | analytical validation, sample stability, and clinical evaluation of a new high-sensitivity cardiac troponin i immunoassay for use in dogs, with comparison to a previous ultrasensitive assay |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10353792/ https://www.ncbi.nlm.nih.gov/pubmed/37463140 http://dx.doi.org/10.1371/journal.pone.0288801 |
work_keys_str_mv | AT wesselowskisonya analyticalvalidationsamplestabilityandclinicalevaluationofanewhighsensitivitycardiactroponiniimmunoassayforuseindogswithcomparisontoapreviousultrasensitiveassay AT lidburyjonathan analyticalvalidationsamplestabilityandclinicalevaluationofanewhighsensitivitycardiactroponiniimmunoassayforuseindogswithcomparisontoapreviousultrasensitiveassay AT saundersashleyb analyticalvalidationsamplestabilityandclinicalevaluationofanewhighsensitivitycardiactroponiniimmunoassayforuseindogswithcomparisontoapreviousultrasensitiveassay AT gordonsonyag analyticalvalidationsamplestabilityandclinicalevaluationofanewhighsensitivitycardiactroponiniimmunoassayforuseindogswithcomparisontoapreviousultrasensitiveassay AT suchodolskijans analyticalvalidationsamplestabilityandclinicalevaluationofanewhighsensitivitycardiactroponiniimmunoassayforuseindogswithcomparisontoapreviousultrasensitiveassay AT steinerjoergm analyticalvalidationsamplestabilityandclinicalevaluationofanewhighsensitivitycardiactroponiniimmunoassayforuseindogswithcomparisontoapreviousultrasensitiveassay |